Prime Medicine (PRME) Accumulated Expenses (2021 - 2026)

Prime Medicine (PRME) has 6 years of Accumulated Expenses data on file, last reported at $8.1 million in Q1 2026.

• Quarterly Accumulated Expenses fell 11.89% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 million (down 11.89% YoY) and the FY2025 annual result came in at $12.6 million, down 20.77% from the prior year.
• Accumulated Expenses declined to $8.1 million in Q1 2026, from $12.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $18.7 million in Q3 2024 to a low of $300000.0 in Q2 2023.
• A 5-year average of $10.6 million and a median of $10.9 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses tumbled 71.26% — and 2024, when it jumped 3531.67%.
• Tracing PRME's Accumulated Expenses over 5 years: stood at $10.7 million in 2022, then surged by 32.02% to $14.1 million in 2023, then rose by 12.71% to $15.9 million in 2024, then declined by 20.77% to $12.6 million in 2025, then tumbled by 35.73% to $8.1 million in 2026.
• The last three Accumulated Expenses figures came in at $8.1 million (Q1 2026), $12.6 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.